# US 2024/0002840 A1 · Novel omni-50 crispr nuclease-rna complexes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002840 A1
- Document ID: US20240002840A1
- Status: Published application
- Kind: A1
- Application number: 18/251,667
- Filed: 2021-11-03
- Published: 2024-01-04
- Earliest claimed: 2020-11-04
- Assignees: Liat ROCKAH; EmendoBio Inc.
- Applicants: EmendoBio Inc.
- Inventors: Lior Izhar; Liat Rockah; Nadav Marbach Bar
- Web page: https://patentgrep.com/patent/US20240002840A1

## CPC

- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/907: {in mammalian cells}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A composition comprising a non-naturally occurring RNA molecule, the RNA molecule comprising an RNA scaffold portion, the RNA scaffold portion having the structure: crRNA repeat sequence portion-Linker portion-tracrRNA portion; wherein the RNA scaffold portion forms a complex with and targets an OMNI-50 CRISPR nuclease to a DNA target site having complementarity to a guide sequence portion of the RNA molecule.

## Claims

### Claim 1

A composition comprising a non-naturally occurring RNA molecule, the RNA molecule comprising a crRNA repeat sequence portion and a guide sequence portion, wherein the RNA molecule forms a complex with and targets an OMNI-50 nuclease to a DNA target site in the presence of a tracrRNA sequence, wherein the tracrRNA sequence is encoded by a tracrRNA portion of the RNA molecule or a tracrRNA portion of a second RNA molecule.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the crRNA repeat sequence portion is less than 17 nucleotides in length, preferably 12-16 nucleotides in length, or wherein the crRNA repeat sequence portion is 17 or more nucleotides in length, preferably 18-24 nucleotides in length.

### Claim 3 (depends on 1, 2)

The composition of claim 1 or 2, wherein the crRNA repeat sequence portion has at least 71-80%, 81-90%, 91-95%, or 96-99% sequence identity to a mature OMNI-50 crRNA repeat sequence encoded by Ezakiella peruensis strain M6.X2.

### Claim 4 (depends on 1, 2, 3)

The composition of any one of claims 1-3, wherein the crRNA repeat sequence portion has at least 60-70%, 71-80%, 81-90%, 91-95%, or 96-99% sequence identity to SEQ ID NO: 23.

### Claim 5 (depends on 1, 2, 3, 4)

The composition of any one of claims 1-4, wherein the crRNA repeat sequence portion has at least 95% sequence identity to any one of SEQ ID NOs: 8, 23, 24, and 25.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1-5, wherein the crRNA repeat sequence is other than SEQ ID NO: 8 or 23.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1-6, wherein the RNA molecule comprising the crRNA repeat sequence portion and the guide sequence portion further comprises the tracrRNA portion.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the crRNA repeat sequence portion is covalently linked to the tracrRNA portion by a polynucleotide linker portion.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1-6, wherein the composition comprises a second RNA molecule comprising the tracrRNA portion.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The composition of any one of claims 1-9, wherein the OMNI-50 nuclease has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The composition of any one of claims 1-10, wherein the guide sequence portion is 17-30 nucleotides in length, preferably 22 nucleotides in length.

### Claim 12

A composition comprising a non-naturally occurring RNA molecule, the RNA molecule comprising a tracrRNA portion, wherein the RNA molecule forms a complex with and targets an OMNI-50 nuclease to a DNA target site in the presence of a crRNA repeat sequence portion and a guide sequence portion, wherein the crRNA repeat sequence portion and the guide sequence portion are encoded by the RNA molecule or a second RNA molecule.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the tracrRNA portion is less than 91 nucleotides in length, preferably 90-80, 89-80, 79-70, 69-60, 59-50, 49-40, or 39-28 nucleotides in length, or wherein the tracrRNA portion is 91 or more nucleotides in length, preferably 91-112 nucleotides in length.

### Claim 14 (depends on 12, 13)

The composition of claim 12 or 13, wherein the tracrRNA portion has at least 30-40%, 41-50%, 51-60%, 61-70%, 71-80%, 81-90%, 91-95%, or 96-99% sequence identity to a mature OMNI-50 tracrRNA sequence encoded by Ezakiella peruensis strain M6.X2.

### Claim 15 (depends on 12, 13, 14)

The composition of any one of claims 12-14, wherein the tracrRNA portion has at least 30-40%, 41-50%, 51-60%, 61-70%, 71-80%, 81-90%, 91-95%, or 96-99% sequence identity to the tracrRNA portion of SEQ ID NO: 5.

### Claim 16 (depends on 12, 13, 14, 15)

The composition of any one of claims 12-15, wherein the tracrRNA portion has at least 95% sequence identity to the tracrRNA portions of any one of SEQ ID NOs: 4, 5, 16-21, 29-31, 74-126, 132-137, and 148-167.

### Claim 17 (depends on 12, 13, 14, 15, 16)

The composition of any one of claims 12-16, wherein the tracrRNA portion is other than the tracr portion of SEQ ID NO: 4 or 5.

### Claim 18 (depends on 12, 13, 14, 15, 16, 17)

The composition of any one of claims 12-17, wherein the tracrRNA portion comprises a tracrRNA anti-repeat sequence portion that is less than 19 nucleotides in length, preferably 14-18 nucleotides in length.

### Claim 19 (depends on 12, 13, 14, 15, 16, 17, 18)

The composition of any one of claims 12-18, wherein the tracrRNA portion comprises a tracrRNA anti-repeat sequence portion that has at least 60-70%, 71-80%, 81-90%, 91-95%, or 96-99% sequence identity to SEQ ID NO: 26.

### Claim 20 (depends on 12, 13, 14, 15, 16, 17, 18, 19)

The composition of any one of claims 12-19, wherein the tracrRNA portion comprises a tracrRNA anti-repeat sequence portion that has at least 95% sequence identity to any one of SEQ ID NOs: 9, 26-28, and 138.

### Claim 21 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20)

The composition of any one of claims 12-20, wherein the tracrRNA portion comprises a tracrRNA anti-repeat sequence portion is other than SEQ ID NO: 9 or 26.

### Claim 22 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The composition of any one of claims 12-21, wherein the RNA molecule comprises a tracrRNA portion and further comprises a crRNA repeat sequence portion and a guide sequence portion.

### Claim 23 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The composition of any one of claims 12-22, wherein the tracrRNA portion is covalently linked to the crRNA repeat sequence by a polynucleotide linker portion.

### Claim 23 (depends on 29, 30, 31, 32, 33, 34)

The composition of any one of claims 29-34, wherein the crRNA repeat sequence portion has at least 95% sequence identity to any one of SEQ ID NOs: 8, 23, 24, and 25.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the polynucleotide linker portion is 4-10 nucleotides in length.

### Claim 25 (depends on 24)

The composition of claim 24, wherein the polynucleotide linker has a sequence of GAAA.

### Claim 26 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The composition of any one of claims 12-21, the composition further comprises a second RNA molecule comprising a crRNA repeat sequence portion and a guide sequence portion.

### Claim 27 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The composition of any one of claims 12-26, wherein the OMNI-50 nuclease is at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 28 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The composition of any one of claims 12-27, wherein the guide sequence portion is 17-30 nucleotides in length, preferably 22 nucleotides in length.

### Claim 29

A composition comprising a non-naturally occurring RNA molecule, the RNA molecule comprising an RNA scaffold portion, the RNA scaffold portion having the structure:
crRNA repeat sequence portion-Linker portion-tracrRNA portion;
wherein the RNA scaffold portion froms a complex with and targets an OMNI-50 CRISPR nuclease to a DNA target site having complimentarity to a guide sequence portion of the RNA molecule.

### Claim 30 (depends on 29)

The composition of claim 29, wherein the RNA scaffold portion is 112, 111-110, 109-105, 104-100, 99-95, 94-90, 89-85, 84-80, 79-75, 74-70, 69-50, or 49-45 nucleotides in length.

### Claim 31 (depends on 29, 30)

The composition of claim 29 or 30, wherein the RNA scaffold portion has at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, or at least 95% sequence identity to SEQ ID NO: 5.

### Claim 32 (depends on 29, 30, 31)

The composition of any one of claims 29-31, wherein the crRNA repeat sequence portion is less than 17 nucleotides in length, preferably 12-16 nucleotides in length, or wherein the crRNA repeat sequence portion is 17 or more nucleotides in length, preferably 18-24 nucleotides in length.

### Claim 33 (depends on 29, 30, 31, 32)

The composition any one of claims 29-32, wherein the crRNA repeat sequence portion has at least 60-70%, 71-80%, 81-90%, 91-95%, or 96-99% sequence identity to a mature OMNI-50 crRNA repeat sequence encoded by Ezakiella peruensis strain M6.X2.

### Claim 34 (depends on 29, 30, 31, 32, 33)

The composition any one of claims 29-33, wherein the crRNA repeat sequence portion has at least 60-70%, 71-80%, 81-90%, 91-95%, or 96-99% sequence identity to SEQ ID NO:

### Claim 36 (depends on 29, 30, 31, 32, 33, 34, 35)

The composition of any one of claims 29-35, wherein the crRNA repeat sequence is other than SEQ ID NO: 8 or 23.

### Claim 37 (depends on 29, 30, 31, 32, 33, 34, 35, 36)

The composition of any one of claims 29-36, wherein the tracrRNA portion is less than 91 nucleotides in length, preferably 90-80, 89-80, 79-70, 69-60, 59-50, 49-40, or 39-28 nucleotides in length, or wherein the tracrRNA portion is 91 or more nucleotides in length, preferably 91-112 nucleotides in length.

### Claim 38 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37)

The composition of any one of claims 29-37, wherein the tracrRNA portion has at least 30-40%, 41-50%, 51-60%, 61-70%, 71-80%, 81-90%, 91-95%, or 96-99% sequence identity to a mature OMNI-50 tracrRNA sequence encoded by Ezakiella peruensis strain M6.X2.

### Claim 39 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The composition of any one of claims 29-38, wherein the tracrRNA portion has at least 30-40%, 41-50%, 51-60%, 61-70%, 71-80%, 81-90%, 91-95%, or 96-99% sequence identity to the tracrRNA portion of SEQ ID NO: 5.

### Claim 40 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The composition of any one of claims 29-39, wherein the tracrRNA portion has at least 95% sequence identity to the tracrRNA portion of any one of SEQ ID NOs: 4, 5, 16-21, 29-31, 74-126, 132-137, and 148-167.

### Claim 41 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The composition of any one of claims 29-40, wherein the tracrRNA portion is other than the tracrRNA portion of SEQ ID NO: 4 or 5.

### Claim 42 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The composition of any one of claims 29-41, wherein the tracrRNA portion comprises a tracrRNA anti-repeat sequence portion, wherein the crRNA repeat sequence and the tracrRNA anti-repeat sequence portion are covalently linked by the linker portion.

### Claim 43 (depends on 42)

The compoisiton of claim 42, wherein the linker portion is a polynucleotide linker that is 4-10 nucleotides in length.

### Claim 44 (depends on 42, 43, 44)

The composition of claim 43, the polynucleotide linker has a sequence of GAAA. The composition of any one of claims 42-44, wherein the tracrRNA anti-repeat sequence portion is less than 19 nucleotides in length, preferably 14-18 nucleotides in length.

### Claim 46 (depends on 42, 43, 44, 45)

The composition of any one of claims 42-45, wherein the tracrRNA portion comprises a tracrRNA anti-repeat sequence portion that has at least 60-70%, 71-80%, 81-90%, 91-95%, or 96-99% sequence identity to SEQ ID NO: 5.

### Claim 47 (depends on 42, 43, 44, 45, 46)

The composition of any one of claims 42-46, wherein the tracrRNA anti-repeat sequence portion has at least 95% sequence identity to any one of SEQ ID NOs: 9, 26-28, and 138.

### Claim 48 (depends on 42, 43, 44, 45, 46, 47)

The composition of any one of claims 42-47, wherein the tracrRNA anti-repeat sequence portion is other than SEQ ID NO: 9 or 26.

### Claim 49 (depends on 42, 43, 44, 45, 46, 47, 48)

The composition of any one of claims 42-48, wherein the tracrRNA portion comprises a first section of nucleotides linked to the tracrRNA anti-repeat portion, and the first section of nucleotides has at least 95% sequence identity to any one of SEQ ID NOs: 10, 11, 127, 128, 139-143, AAC, A, AA, AAA, and ACAAACC.

### Claim 50 (depends on 42, 43, 44, 45, 46, 47, 48, 49)

The composition of any one of claims 42-49, wherein the tracrRNA portion comprises a second section of nucleotides linked to a first section of nucleotides, and the second section of nucleotides has at least 95% sequence identity to any one of SEQ ID NOs: 12, 32, 144-146, GCCUAUU, GCCUAU, AAUGGC, AAAGGC, UAUAGGC, AUAGGC, and GCCU.

### Claim 51 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50)

The composition of any one of claims 42-50, wherein the tracrRNA portion comprises a third section of nucleotides linked to a second section of nucleotides, and the third section of nucleotides has at least 95% sequence identity to any one of SEQ ID NOs: 13, 33, 34, 129, 130, 147, CGCAG, CGC, CGCAGG, C, CUUCUGC, and CGCAGUUG.

### Claim 52 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The composition of any one of claims 42-51, wherein the tracrRNA portion comprises a fourth portion of nucleotides linked to a third section of nucletides, and the fourth section of nucleotides has at least 95% sequence identity to any one of SEQ ID NOs: 14, 15, 35-73, 131, AUU, AUUAUUU, AUUU, AUUUUUUUU, AGCUUUUUU, UUUU, UUUUU, and UUU.

### Claim 53 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The composition of any one of claims 29-52, wherein the RNA scaffold portion has at least 95% identity to the nucleotide sequence of SEQ ID NO: 4, 5, 16-21, 29-31, 74-126, 132-137, and 148-167.

### Claim 54 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The composition of any one of claims 29-53, wherein the RNA scaffold portion has a predicted structure of any one of the Full F, Full C, Short 1, Short 2, Short 3, Short 4, Short Short 6, NGS13, NGS14, NGS15, NGS16, NGS17, NGS18, NGS40, NGS41, NGS42, NGS43, NGS44, NGS9, NGS2, NGS3, NGS12, NGS1, or NGS6 RNA scaffolds.

### Claim 55 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The composition of any one of claims 29-54, wherein the RNA scaffold portion is other than SEQ ID NO: 4 or 5.

### Claim 56 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The composition of any one of claims 29-55, wherein the guide sequence portion is covalently linked to the crRNA repeat sequence portion of the RNA molecule, forming a single-guide RNA molecule having a stucture:
Guide sequence portion-crRNA repeat sequence portion-Linker portion-tracrRNA portion.

### Claim 57 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The composition of any one of claims 29-56, wherein the guide sequence portion is 17-30 nucleotides, more preferably 20-23 nucleotides, more preferably 22 nucleotides in length.

### Claim 58 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The composition of any one of claims 29-57, further comprising an OMNI-50 CRISPR nuclease, wherein the OMNI-50 CRISPR nuclease has at least 95% identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 59 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The composition of any one of claims 29-58, wherein the RNA molecule is formed by in vitro transcription (IVT) or solid-phase artificial oligonucleotide synthesis.

### Claim 60 (depends on 59)

The composition of claim 59, wherein the RNA molecule comprises modified nucleotides.

### Claim 61 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

A polynucleotide molecule encoding the RNA molecule of any one of claims 29-56.

### Claim 62 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

A method of modifying a nucleotide sequence at a DNA target site in a cell-free system or a genome of a cell comprising introducing into the system or cell the composition of any one of claims 29-56 and an OMNI-50 CRISPR nuclease.

### Claim 63 (depends on 62)

The method of claim 62, wherein the cell is a eukaryotic cell or a prokaryotic cell.

### Claim 64 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

A kit for modifying a nucleotide sequence at a DNA target site in a cell-free system or a genome of a cell comprising introducing into the system or cell the composition of any one of claims 29-56, an OMNI-50 CRISPR nuclease, and instructions for delivering the RNA molecule and the OMNI-50 CRISPR nuclease to the cell.
